MiMedx Group, Inc. (NASDAQ:MDXG) Given Consensus Rating of "Buy" by Analysts

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) has been assigned an average recommendation of "Buy" from the four brokerages that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $12.25.

Several research analysts recently commented on MDXG shares. Lake Street Capital initiated coverage on MiMedx Group in a research report on Thursday, March 7th. They issued a "buy" rating and a $12.00 target price for the company. Mizuho increased their price objective on MiMedx Group from $13.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, March 1st.

Insider Activity

In other news, COO Ricci S. Whitlow sold 15,493 shares of the firm's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $8.07, for a total value of $125,028.51. Following the completion of the sale, the chief operating officer now directly owns 416,321 shares in the company, valued at $3,359,710.47. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, COO Ricci S. Whitlow sold 15,493 shares of the firm's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $8.07, for a total value of $125,028.51. Following the completion of the sale, the chief operating officer now directly owns 416,321 shares in the company, valued at $3,359,710.47. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO William Frank Iv Hulse sold 20,381 shares of the firm's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the sale, the chief accounting officer now owns 479,959 shares of the company's stock, valued at $3,815,674.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,145 shares of company stock worth $409,378. 19.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On MiMedx Group

Hedge funds have recently added to or reduced their stakes in the company. AJOVista LLC bought a new position in MiMedx Group in the fourth quarter valued at about $25,000. Squarepoint Ops LLC bought a new position in MiMedx Group in the fourth quarter valued at about $28,000. DekaBank Deutsche Girozentrale bought a new position in MiMedx Group in the third quarter valued at about $38,000. Fairfield Bush & CO. bought a new position in MiMedx Group in the second quarter valued at about $51,000. Finally, Delphia USA Inc. bought a new position in MiMedx Group in the first quarter valued at about $55,000. Institutional investors own 79.15% of the company's stock.

MiMedx Group Stock Performance

MiMedx Group stock traded down $0.25 during trading hours on Monday, reaching $7.45. 1,095,622 shares of the company were exchanged, compared to its average volume of 769,565. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 24.06 and a beta of 1.32. The company has a current ratio of 3.57, a quick ratio of 3.11 and a debt-to-equity ratio of 0.34. The stock has a 50-day moving average of $8.03 and a 200 day moving average of $7.69. MiMedx Group has a 12 month low of $3.08 and a 12 month high of $9.27.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $86.83 million during the quarter, compared to the consensus estimate of $85.58 million. MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. As a group, research analysts anticipate that MiMedx Group will post 0.33 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.